HRTX — HERON THERAPEUTICS, INC. /DE/
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 818033 ·
Last close
$0.36
Market Cap
$68.01M
52W High
$1.58
52W Low
$0.26
ADV30
2,278,158
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 37,666,000 | 26,094,000 | -2,044,000 | -5,489,000 | 252,262,000 | 20,721,000 | 245,354,000 |
| Mar 2026 | 34,711,000 | 24,073,000 | -4,765,000 | -8,111,000 | 246,216,000 | 26,117,000 | 237,079,000 |
| Dec 2025 | 40,588,000 | 29,469,000 | 38,000 | -2,954,000 | 255,877,000 | 28,647,000 | 241,544,000 |
| Sep 2025 | 38,213,000 | 26,299,000 | -4,093,000 | -17,495,000 | 248,950,000 | 43,068,000 | 234,065,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-20,261,000
Investing CF
$12,797,000
Financing CF
$14,312,000
CapEx
$-1,346,000
Dividends Paid
—
Buybacks
$-51,000
EPS Diluted TTM
$-0.18
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,947,900,000
Inventory
$92,539,000
Receivables
$83,693,000
ST Investments
$18,667,000
EBIT TTM
$-18,509,000
Pretax Income TTM
$-30,941,000
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$151,178,000
EBITDA
$-8,731,000
Free Cash Flow
$-8,837,125
Enterprise Value
$166,638,400
Total Cash
$42,664,000
Total Debt
$148,354,000
Shares Out
189,852,307
Trailing EPS
$-0.19
Book Value
$0.03
ROE
—
ROA
-2.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 154,904,000 | -2,538,000 | -20,195,000 | 255,877,000 | 241,544,000 | 14,333,000 | -27,591,000 |
| Dec 2024 | 144,285,000 | -11,528,000 | -13,580,000 | 233,147,000 | 266,798,000 | -33,651,000 | -22,529,000 |
| Dec 2023 | 127,044,000 | -110,615,000 | -110,559,000 | 222,506,000 | 256,479,000 | -33,973,000 | -58,789,000 |
| Dec 2022 | 107,672,000 | -174,658,000 | -182,024,000 | 250,951,000 | 237,379,000 | 13,572,000 | -146,912,000 |
TTM Snapshot
Revenues TTM
$150,712,000
NetIncome TTM
$-30,941,000
OpCashFlow TTM
—
Assets (Latest)
$246,216,000
Forward EPS
$-0.11
Max Pain — expiry 2026-10-16
max pain strike: $0.50 · spot: $0.36 · call oi: 24 · put oi: 20,981
Expected Move to 2026-10-16:
±$0.19
(52.78%) —
implied range
$0.17 –
$0.55
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NMAD | NOMAD POWER SOLUTIONS, INC. | $68.75M | $4.27 | — |
| HYFT | MindWalk Holdings Corp. | $67.19M | $1.43 | — |
| XBIT | XBiotech Inc. | $67.07M | $2.20 | — |
| ONCY | ONCOLYTICS BIOTECH INC | $69.42M | $0.54 | — |
| TENX | TENAX THERAPEUTICS, INC. | $69.61M | $1.86 | — |
News headlines (Yahoo Finance, 1h cache)
Heron Therapeutics Inc (HRTX) (Q2 2026) Earnings Call Highlights: Revenue Growth Amid Strategic ...
2026-08-10 21:01 · Yahoo
Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook
2026-08-10 15:05 · Yahoo
Heron Therapeutics Q2 Earnings Call Highlights
2026-08-10 14:04 · Yahoo
Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates
2026-08-10 13:10 · Yahoo
Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026
2026-07-27 12:30 · Yahoo
Heron Therapeutics (HRTX) Stock Sees Fair Value Cut After Cinvanti Patent Decision
2026-07-12 00:16 · Yahoo
U.S. District Court Issues Decision Regarding CINVANTI® Patents
2026-06-02 12:12 · Yahoo
Heron Therapeutics Inc (HRTX) Q1 2026 Earnings Call Highlights: Resilient Growth Amidst Challenges
2026-05-12 07:02 · Yahoo
Acute Care Revenue Growth Helps Heron (HRTX) Reaffirm 2026 Guidance Despite Q1 Sales Decline
2026-05-11 15:03 · Yahoo
Heron Therapeutics Q1 Earnings Call Highlights
2026-05-11 15:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.